Sign in to view content

Low-Dose Atropine 0.01% Drops for Symptomatic Vitreous Floaters: A Noninvasive, Safe, and Effective Therapeutic Option

Mohsin H. Ali, MD

Video
Published 2025

Related

Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2021
Real-World Visual Outcomes After YAG Vitreolysis for Vitreous Opacities (VOYAGE)
Netan Choudhry, MD, FRCS(C) FASRS
Annual Meeting Talks
2020
Wavefront Aberrometry in Pseudophakic Patients Before and After Vitrectomy for Bothersome Floaters
Daniel A. Adelberg, MD, FASRS
Annual Meeting Talks
2021

Category: Pharmacology

See more